AUPH
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
Aurinia Pharmaceuticals Inc. (AUPH) is scored daily on Deltasharpe Prism against Healthcare sector peers across five pillars: Value, Growth, Profitability, Momentum and Revisions.
Quantitative Factor Evaluation • Updated
Subscribe to unlock
Subscribe to unlock
Subscribe to unlock
Subscribe to unlock
Subscribe to unlock
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-17 | B (3.3) | C (2.3) | B (3.4) | B (3.2) | C+ (2.6) | B- (3.0) |
| 2026-11-10 | B (3.3) | C (2.3) | B (3.4) | B (3.3) | C+ (2.6) | B- (3.0) |
| 2026-11-03 | B (3.2) | C (2.3) | B (3.4) | B (3.2) | C+ (2.7) | B- (3.0) |
| 2026-10-27 | B (3.2) | C+ (2.7) | B (3.2) | B- (3.1) | C+ (2.6) | B- (3.0) |
| 2026-10-20 | B (3.2) | C+ (2.6) | B (3.2) | B- (3.0) | C+ (2.6) | B- (3.0) |
Showing the last month only. Subscribe for the full factor score history.
For more — Subscribe